Pacira BioSciences (PCRX): Viatris to buy it for $1.65B in cash
Image: AI-generated image (ElevenLabs)
Viatris agreed to buy Pacira for $36.50 a share in cash, about $1.65B, a ~44.8% premium to its last close. Pacira's non-opioid pain drugs Exparel and Zilretta bring ~$746M of trailing revenue. Close targeted by end-2026 via tender offer.
Why it matters Viatris is paying up for a non-opioid pain franchise with about $177M of adjusted EBITDA. Shareholders get a clear cash exit, but the deal still needs a majority tender and regulatory clearance.
What we verified Pacira's Oct 8, 2026 8-K confirms $36.50 per share in cash, about $1.65B, a tender offer then merger, and a close expected by end-2026. Reuters (via KSL) matches the terms and reports the 44.8% premium.
More on Pacira BioSciences (PCRX) · Healthcare takes
Run the numbers yourself Try the investment calculators on persie.app . They are tools, not advice.
For information only. Not financial advice. See our disclaimer and editorial standards . Spotted an error? Tell us .
